CO4440626A1 - Amidas terapeuticas - Google Patents

Amidas terapeuticas

Info

Publication number
CO4440626A1
CO4440626A1 CO96029732A CO96029732A CO4440626A1 CO 4440626 A1 CO4440626 A1 CO 4440626A1 CO 96029732 A CO96029732 A CO 96029732A CO 96029732 A CO96029732 A CO 96029732A CO 4440626 A1 CO4440626 A1 CO 4440626A1
Authority
CO
Colombia
Prior art keywords
radicals
alcoxi
pharmaceutically acceptable
formula
direct link
Prior art date
Application number
CO96029732A
Other languages
English (en)
Inventor
George Chang
Peter H Dorff
George J Quallich
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1995/000448 external-priority patent/WO1996040640A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of CO4440626A1 publication Critical patent/CO4440626A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals
    • C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REIVINDICACION UN COMPUESTO DE FORMULA I FIGURA 1 EN LA QUE X ES CH2, CO, CS o SO2; Y SE SELECCIONA ENTRE: UN ENLACE DIRECTO, RADICALES HIDROCARBILENO ALIFATICOS DE HASTA 20 A- TOMOS DE CARBONO QUE PUEDEN ESTAR MONOSUBSTITUIDOS CON HIDROXI, ALCOXI(C1-C10), ACILO (C1-C10), ACI- LOXI (C1-C10) O ARILO (C1-C10), NH y O, CON LA CONDICION DE QUE SE X ES CH2, Y ES UN ENLA- CE DIRECTO; Z SE SELECCIONA ENTRE LOS SIGUIENTES GRUPOS: (1) H, HALO, CIANO, (2) HIDROXI, ALCOXI... (3) ALQUILAMINO... (4) VINILO NO SUSTITUIDO... (5) ARILOXI... (6) HETEROCICLILO SELECCIONADO DEL GRUPO COMPUESTO POR RADICALES MONOCICLICOS Y RADICALES POLICICLI- COS CONDENSADOS... Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DEL MIS- MO. REIVINDICACION 2UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN COM- PUESTO DE FORMULA I CONFORME A LO DEFINIDO EN LA REIVINDICACION 1, Y UN VEHICULO FARMACEUTICAMENTE ACEPTABLE.
CO96029732A 1995-06-07 1996-06-07 Amidas terapeuticas CO4440626A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB1995/000448 WO1996040640A1 (en) 1995-06-07 1995-06-07 BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Publications (1)

Publication Number Publication Date
CO4440626A1 true CO4440626A1 (es) 1997-05-07

Family

ID=11004342

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96029732A CO4440626A1 (es) 1995-06-07 1996-06-07 Amidas terapeuticas

Country Status (20)

Country Link
US (1) US5919795A (es)
KR (1) KR100225713B1 (es)
AR (1) AR003424A1 (es)
AT (1) ATE233734T1 (es)
AU (1) AU703493B2 (es)
BG (1) BG62442B1 (es)
CO (1) CO4440626A1 (es)
DE (1) DE69529849T2 (es)
DK (1) DK0832069T3 (es)
DZ (1) DZ2045A1 (es)
IL (3) IL135376A0 (es)
MA (1) MA23895A1 (es)
MX (1) MX9709914A (es)
OA (1) OA10363A (es)
RO (1) RO116897B1 (es)
RU (1) RU2141478C1 (es)
TN (1) TNSN96085A1 (es)
TR (1) TR199600481A2 (es)
TW (1) TW476756B (es)
YU (1) YU35296A (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9709137A (pt) * 1996-04-30 1999-08-03 Pfizer Processos e intermediários para a preparação de [2-(2H-[1,2,4]triazol-3-ilmetil)-1,2,3,4-tetra-hidro-isoquinolin-6-il]-amida do ácido 4'-trifluorometilbifenil-2-carboxílico
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
WO2001053260A1 (en) * 2000-01-18 2001-07-26 Novartis Ag Carboxamides useful as inhibitors of microsomal triglyceride transfer protein and of apolipoprotein b secretion
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2409B1 (en) * 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
US6953671B2 (en) * 2001-02-23 2005-10-11 The Trustees Of Columbia University In The City Of New York Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action
AU2002307839B2 (en) 2001-06-28 2006-03-16 Zoetis P Llc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (MTP) and/or apolipoprotein B (Apo B) secretion
AU2003230665B2 (en) * 2002-03-13 2010-02-18 University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2005051298A2 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US20080207685A1 (en) * 2003-11-20 2008-08-28 Eli Lilly And Company Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
KR100799802B1 (ko) * 2004-02-04 2008-01-31 화이자 프로덕츠 인크. 치환된 퀴놀린 화합물
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
AU2006236226B2 (en) * 2005-04-19 2012-07-05 Surface Logix, Inc. Inhibitors of microsomal triglyceride transfer protein and Apo-B secretion
CA2609783A1 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
EP3431602A1 (en) * 2006-04-03 2019-01-23 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
JP5814505B2 (ja) 2006-04-03 2015-11-17 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ ａｎｔｉｍｉＲＮＡアンチセンスオリゴヌクレオチドを含む医薬組成物
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
US20100216864A1 (en) * 2006-10-09 2010-08-26 Ellen Marie Straarup RNA Antagonist Compounds for the Modulation of PCSK9
US20100210633A1 (en) * 2006-10-12 2010-08-19 Epix Delaware, Inc. Carboxamide compounds and their use
DK2149605T3 (da) * 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
AU2008228243B2 (en) * 2007-03-22 2014-05-15 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
US20110054011A1 (en) * 2007-08-30 2011-03-03 Mccullagh Keith RNA Antagonist Compounds for the Modulation of FABP4/AP2
AU2008306327B2 (en) * 2007-10-04 2014-05-15 Roche Innovation Center Copenhagen A/S Micromirs
US8569282B2 (en) 2007-12-11 2013-10-29 Cytopathfinder, Inc. Carboxamide compounds and their use
US8404659B2 (en) * 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
US8309734B2 (en) * 2008-10-29 2012-11-13 Hoffmann-La Roche Inc. Substituted pyridines as GPBAR1 agonists
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
WO2010122538A1 (en) * 2009-04-24 2010-10-28 Santaris Pharma A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
WO2010127208A1 (en) * 2009-04-30 2010-11-04 Forest Laboratories Holdings Limited Inhibitors of acetyl-coa carboxylase
US20100280067A1 (en) * 2009-04-30 2010-11-04 Pakala Kumara Savithru Sarma Inhibitors of acetyl-coa carboxylase
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
EP2640704A1 (en) * 2010-11-15 2013-09-25 Abbvie Inc. Nampt inhibitors
CN112263682A (zh) 2013-06-27 2021-01-26 罗氏创新中心哥本哈根有限公司 靶向pcsk9的反义寡聚体和缀合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
DK410183A (da) * 1982-09-10 1984-03-11 Wellcome Found 2-(substitueret-phenyl)-benzoesyrederivater, fremgangsmaade til deres fremstilling samt deres anvendelse
GB9127306D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5246943A (en) * 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
US5731324A (en) * 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
IL110172A (en) * 1993-07-22 2001-10-31 Lilly Co Eli Bicycle compounds and pharmaceuticals containing them
YU23499A (sh) * 1996-11-27 2001-07-10 Pfizer Inc. Inhibitorski amidi apo-b-sekrecije/mtp-a

Also Published As

Publication number Publication date
YU35296A (sh) 1999-06-15
IL135377A0 (en) 2001-05-20
TW476756B (en) 2002-02-21
DK0832069T3 (da) 2003-04-22
TNSN96085A1 (fr) 2005-03-15
MA23895A1 (fr) 1996-12-31
US5919795A (en) 1999-07-06
AU703493B2 (en) 1999-03-25
RO116897B1 (ro) 2001-07-30
BG100637A (bg) 1997-03-31
BG62442B1 (bg) 1999-11-30
DZ2045A1 (fr) 2002-07-21
OA10363A (en) 2001-11-15
ATE233734T1 (de) 2003-03-15
DE69529849T2 (de) 2003-09-04
MX9709914A (es) 1998-03-31
IL135375A0 (en) 2001-05-20
IL135376A (en) 2001-05-20
RU2141478C1 (ru) 1999-11-20
AU5478496A (en) 1996-12-19
TR199600481A2 (tr) 1996-12-21
DE69529849D1 (de) 2003-04-10
IL135377A (en) 2001-05-20
KR100225713B1 (ko) 1999-10-15
IL135375A (en) 2001-07-24
IL135376A0 (en) 2001-05-20
AR003424A1 (es) 1998-08-05
KR970003589A (ko) 1997-01-28

Similar Documents

Publication Publication Date Title
CO4440626A1 (es) Amidas terapeuticas
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
HUT65689A (en) Process for producing sulfonamides and pharmaceutical preparations containing them
GR3018541T3 (en) Condensed heterocyclic compounds and their use in therapy.
DE3271532D1 (en) Salts of n-substituted-2-pyrrolidone-4-carboxylic acids as humectants
ATE38672T1 (de) 7-oxabicycloheptan aminosubstituierte prostaglandinaehnliche verbindungen.
DE3486235T2 (de) Fettsäure-Zusammensetzungen.
FR2521857B1 (fr) Compositions pharmaceutiques contenant de l'acide 3-hydroxybutanoique ou un sel derive de cet acide et sels derives de l'acide 3-hydroxybutanoique et d'une base organique azotee
IL91369A0 (en) Lfa-1alpha subunit and derivatives thereof free of natural contaminants,and pharmaceutical compositions containing it
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
IT1169912B (it) Accendino, in particolare accendino da gettare
ES2062292T3 (es) Un proceso para la preparacion del compuesto que tiene la estructura (7alfa,17alfa)-17-hidroxi-7-metil-19-nor-17-pregn-5(10)-in-3-ona.
DE3686022D1 (de) Monosaccharide enthaltende zusammensetzung zum heilen von wunden.
PT92558A (pt) Processo para a preparacao de derivados de aminoacidos inibidores de enzimas e de composicoes farmaceuticas que os contem
DK482185A (da) Peptider, deres fremstilling og anvendelse som laegemidler
ES2060163T3 (es) Composicion farmaceutica a base de paracetamol.
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
ATE122886T1 (de) Verwendung von 1,4-dihydropyridin-derivaten in der behandlung von alkoholsucht.
ES2014445B3 (es) Composiciones farmaceuticas que contienen compuestos 5-fenil-1,3-dioxialquenilicos.
DE3465305D1 (en) 2-tolyl-morpholine derivatives for therapeutical use
IT1212137B (it) Composizioni farmaceutiche per il trattamento di sindromi psico-organiche cerebrali.
FR2563135B1 (fr) Dispositif de fermeture des rainures d'une table d'une machine a scier
IT8468265A1 (it) Derivati del 3-fenil-4H-1-benzopirano-4-one per la prevenzione o il trattamento dell'osteoporosi.
IT8322949A0 (it) Composizione farmaceutica utile per il miglioramento e/o il trattamento di sintomi mentali provocati da disturbi organici nel cervello.
ES2116522T3 (es) Compuestos citotoxicos.